ACST (acastipharma.com) Expected net earnings per share growth this year

Official company branding of Acasti Pharma (ACST)

Partnerships with research centers to develop inhalations enhance the investment attractiveness of Acasti Pharma (ACST), as illustrated by the annual EPS growth. The value of -6.60 characterizes this valuation parameter. The development of transmucosal drug delivery accelerates the therapeutic effect, while the preparation of data for the regulator regarding the drug ONP-002 completes the company's current innovation cycle in the cardiology sector.

ACST (Acasti Pharma Inc.) Earnings per share growth in current year history from 07/04/2022 to 10/28/2024

Financial and market metric breakdowns for acastipharma.com (ACST)

- share price and expert price forecast:
Price Acasti Pharma Inc.|ACST - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization ACST|ACST - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Accounting Value of a Share Acasti Pharma|ACST - Company Book Value|Market Capitalization to Net Assets acastipharma.com|ACST - Company Total Assets
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Acasti Pharma|ACST - Long-Term Debt to Capital|Short-Term Debt to Capital Acasti Pharma Inc.|ACST - Company Debts|Debt to Net Assets Ratio ACST|ACST - Company Long-Term Debt|Company Current Liabilities Acasti Pharma|Quick Ratio acastipharma.com
- net income and valuation multiples indicators:
ACST - Net Profit|Projected Future Earnings Acasti Pharma|ACST - P/E Multiple|Projected Price to Earnings Acasti Pharma Inc.|ACST - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio ACST|ACST - Operating profit before deduction of amortization|Earnings per share for the last four quarters Acasti Pharma|ACST - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months acastipharma.com|ACST - Earnings growth in current year|Expected net earnings per share growth next year Acasti Pharma
- revenue and sales proceeds data:
ACST - Revenue and Sales Volume|Projected Sales Volume Acasti Pharma Inc.|ACST - Price-to-Revenue Ratio|Forward Price to Sales ACST
Basic company analysis:Acasti (ACST)
Manufactured products of acastipharma.com

This indicator measures the year-over-year dynamics of earnings per share, reflecting the efficiency of business capitalization and real income growth rates. In the context of Acasti Pharma (ACST), analyzing YoY EPS changes allows for an assessment of how colossal expenditures on cardiology research and patent protection impact final profitability. The stability of this metric determines the fair risk premium amid the uncertainty of clinical trials.

Main competitors

REGN: Net earnings per one share growth for the current year|IRTC (iRhythm Technologies Inc) - Earnings growth in current year|Lantheus Corp (LNTH) - Expected net earnings per share growth this year|Net earnings per share growth this year MLYS (Mineralys Therapeutics)|HTFL (HeartFlow, Inc.) - Earnings per share increase in current year|Earnings per share growth in current year Kestra Medical KMTS|ESPR (Esperion Therapeutics, Inc.) - Earnings per share trend in current year|Amarin Corp - Earnings growth in current year|Earnings per share increase in current year AVR (Anteris Technologies Global)|TNYA: Earnings growth in current year|cvrx.com (CVRX) - Earnings growth in current year|Earnings per share growth in current year Milestone Pharmaceuticals Inc.|CRDL: Earnings per share increase in current year|Earnings per share growth in current year HeartBeam Corp (BEAT)|Net earnings per share growth this year Tenax Therapeutics Inc TENX|Earnings growth in current year ADGM (Adagio Medical Holdings)|Earnings growth in current year biocardia.com BCDA|Catheter Precision, Inc. - Earnings growth in current year|ABIO - Earnings growth in current year|AVTE: Earnings growth in current year|Net earnings per share growth this year Verve Therapeutics, Inc.|Earnings per share growth in current year Windtree Therapeutics Inc.